Recent Updates
Recently added Catalysts
MAZE Positive Sentiment

After FTC stalled Sanofi deal, Shionogi secures Maze’s Pompe disease drug for $150M

Friday, May 10, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Shionogi has acquired Maze's Pompe disease drug for $150 million following a stalled deal with Sanofi due to FTC intervention. This acquisition is seen as a strategic move to bolster Shionogi's offerings in the biopharma sector. The deal highlights the ongoing interest in treatments for Pompe disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • Shionogi successfully secures Maze's Pompe disease drug.
  • The deal is valued at $150 million.
  • This acquisition could enhance Shionogi's portfolio.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
1.8%
average across 3 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
MZE829
Phase 2 · Proteinuric Kidney Disease

Full Press Release Details

• Privacy Overview
• Essential Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
These cookies are necessary for our website to function and for measurement purposes. Opt-out rights do not apply to these cookies.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What drug did Shionogi acquire from Maze?

Shionogi acquired Maze's drug for Pompe disease.

How much did Shionogi pay for the acquisition?

Shionogi secured the drug for $150 million.

Why was the Sanofi deal stalled?

The deal with Sanofi was stalled due to FTC intervention.

What is the significance of this acquisition?

This acquisition enhances Shionogi's portfolio in the biopharma sector.

ShareAdd on Google
Tags: MAZE Viatris Investor Conferences Healthcare Shionogi Maze Pompe disease biopharma FDA
Last updated: May 10, 2024

Biotech snapshot

Cash runway
$495M liquidity · $16M/mo burn
~31 mo
Minimal dilution risk
Lead asset
MZE829Phase 2
Proteinuric Kidney Disease →

Catalyst track record

+9%
best trade around MAZE's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for MAZE.

See every catalyst's timing & PoA →